PTEN and glioblastoma: Thus, developing advanced MMC derivatives being capable of passing through blood–brain barrier and with reduced toxicity may represent a potential therapeutic strategy for GBM harbouring PTEN mutations, despite that the underlying pharmacological mechanism warrants further investigations.